Accelerating Cancer Cures is a multi-million-dollar project that will train a new generation of exceptional clinical investigators capable of translating the latest scientific discoveries into new diagnostics and therapeutics for patients.The initiative also fosters communication and collaboration between academia and industry. Accelerating Cancer Cures is currently sponsored by some of the world’s leading companies: AbbVie, Amgen, Genentech, Merck, and Novartis.
The Collaborators
Accelerating Cancer Cures is supported by leading biopharmaceutical companies who are committed to finding new cures for cancer. Founded in 2011, the initiative has included numerous participants: AbbVie, Amgen, Celgene, Eli Lilly and Company, Genentech, Merck, Novartis, Pfizer, and Takeda Oncology. Competitors in the marketplace, these companies have a shared belief that funding young physician-scientists with a commitment to innovation in cancer research will have a profound impact on the next generation of cancer breakthroughs.
The Awardees
View current and former awardees.